Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 719 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Colitis Clear all
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

NCT05104723
View directory record Official record
Conditions
Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
Interventions
XELJANZ (tofacitinib)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

NCT05507216
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
46
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis

NCT01465763
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

NCT04613518
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
BMS-986165, Placebo Comparator
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
San Diego, California • Arlington Heights, Illinois • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT02819635
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
1,302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
149
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 5:18 PM EDT
Enrolling by invitation Phase 1 Interventional

Fecal Microbiome Transplant

NCT02636517
View directory record Official record
Conditions
Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Judith Kelsen
Other
Eligibility
3 Years to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

NCT03259308
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ontamalimab, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
62
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 3 Interventional

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

NCT00408174
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
88
States / cities
Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Early Phase 1 Interventional

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

NCT03268213
View directory record Official record
Conditions
Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Not applicable Interventional

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

NCT01441271
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Ileal diversion and lavage, total abdominal colectomy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 23, 2026, 5:18 PM EDT
Withdrawn Phase 4 Interventional

Addition of Lactobacillus to Metronidazole in Treatment of CDAD

NCT00304863
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
Interventions
Lactobacillus GG
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 23, 2026, 5:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Effects of L-Arginine in Colitis and Colon Cancer

NCT01091558
View directory record Official record
Conditions
Ulcerative Colitis, Colon Cancer
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 23, 2026, 5:18 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

NCT05176366
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
ExoFlo
Biological
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 23, 2026, 5:18 PM EDT
Completed No phase listed Observational

Exacerbating Factors in Inflammatory Bowel Disease

NCT01405105
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

NCT01290042
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
AMG 181, Placebo for AMG 181
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
5
States / cities
Glendale, California • Bridgeport, Connecticut • Danbury, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 23, 2026, 5:18 PM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 23, 2026, 5:18 PM EDT
Completed Phase 3 Interventional

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064454
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
OPC-6535 Tablets (drug)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 23, 2026, 5:18 PM EDT
Recruiting No phase listed Observational

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07237516
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
11
States / cities
New Haven, Connecticut • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

NCT07513181
View directory record Official record
Conditions
Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Interventions
ATH-063, Placebo
Drug · Other
Lead sponsor
Athos Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Miami, Florida • Tampa, Florida • Roswell, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 23, 2026, 5:18 PM EDT
Not yet recruiting No phase listed Observational

Naturopathic Approaches to Ulcerative Colitis

NCT07521904
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Naturopathic medicine
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 5:18 PM EDT
Recruiting Phase 2 Interventional

Stool Transplants to Treat Refractory Clostridium Difficile Colitis

NCT02127398
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
fecal microbiota
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 5:18 PM EDT